Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

(2017) Tomas Kalincik et al.   LANCET NEUROLOGY

Treatment decisions in multiple sclerosis — insights from real-world observational studies

(2017) Maria Trojano et al.   Nature Reviews Neurology

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

(2017) Johannes Lorscheider et al.   NEUROLOGY

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study

(2016) Marcus D’Souza et al.   Multiple Sclerosis Journal

Data quality evaluation for observational multiple sclerosis registries

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

Observational data: Understanding the real MS world

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study

(2016) Marcus D’Souza et al.   Multiple Sclerosis Journal

Data quality evaluation for observational multiple sclerosis registries

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

Observational data: Understanding the real MS world

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

Defining reliable disability outcomes in multiple sclerosis

(2015) Tomas Kalincik et al.   BRAIN

MatchIt: Nonparametric Preprocessing for Parametric Causal Inference

(2015) Daniel E. Ho et al.   Journal of Statistical Software

Modelling the natural history of primary progressive multiple sclerosis

(2014) Katharine E Harding et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Progressive multiple sclerosis: desperately seeking remedy

(2013) Olaf Stuve et al.   LANCET NEUROLOGY

Treatment trials in progressive MS—current challenges and future directions

(2013) Marcus W. Koch et al.   Nature Reviews Neurology

Treatment of relapsing-remitting multiple sclerosis

(2012) Aaron E. Miller et al.   CURRENT OPINION IN NEUROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

(2010) S. Belachew et al.   EUROPEAN JOURNAL OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

The natural history of primary progressive multiple sclerosis

(2009) M. Koch et al.   NEUROLOGY